1. A pharmaceutical composition comprising minocycline and one or more pharmaceutical^ acceptable excipient(s), wherein said composition comprises (i) about 20 to about 40 percent of minocycline in an immediate release (IR) portion and (ii) about 80 to about 60 percent of minocycline in an extended release (ER) portion; and exhibits at least one of the following dissolution profiles when measured in USP type I apparatus at 100 rpm in 900ml of simulated gastric fluid with a pH of 2.1 and at 37 °C: (a) about 15 % to about 25 % of minocycline in 15 minutes, (b) about 35 % to about 50 % of minocycline in 30 minutes, (c) about 50 % to about 65 % of minocycline in 60 minutes and (d) about 70 % to about 90 % of minocycline in 120 minutes.
2. The composition of claim 1, wherein in said immediate release (IR) and extended release (ER) portions are present in a ratio of about 20:80 to about 40:60.
3. The composition of claim 1, wherein said immediate release (IR) and/or extended release (ER) portion are present in the form of a granule, pellet, bead, spherule, powder and the like or mixtures thereof.
4. The composition of claim 1, wherein the minocycline is minocycline hydrochloride.
5. The composition of claim 1, wherein the composition is substantially free of lactose.
6. The composition of claim 1, wherein the composition comprises a tablet.
7. The tablet of claim 6, wherein said tablet comprises one or more cushioning agent(s) selected from microcrystalline cellulose, silicified microcrystalline cellulose, calcium phosphate, mannitol, sorbitol, polyethylene glycol, sodium stearyl fumarate, magnesium stearate, starch, talc and the like, or mixtures thereof.
8. The tablet of claim 7, wherein said cushioning agent(s) are present in an amount of about 40% to about 60% by weight of the tablet.
9. The tablet of claim 6, wherein said tablet is optionally administered to a subject by dispersing in food dispersion.

10. The tablet of claim 6, wherein said tablet exhibits disintegration time from about 5 minutes to about 17 minutes in food dispersion.
11. The tablet of claim 6, wherein said tablet exhibits disintegration time from about 20 seconds to about 60 seconds in water.
12. The tablet of claim 6, wherein said tablet is stable in food dispersion for at least 1 hour.
13. A once daily oral tablet of minocycline comprising 165mg, 135mg, 115mg, 105mg, or 90mg of minocycline, wherein said tablet comprises (i) an immediate release (IR) portion; (ii) an extended release (ER) portion; and (iii) one or more pharmaceutically acceptable excipients.
14. The tablet of claim 13, wherein said tablet is substantially free of lactose.
15. The tablet of claim 13, wherein said tablet comprises (i) about 20 to about 40 percent of minocycline in an immediate release (IR) portion; (ii) about 80 to about 60 percent of minocycline in an extended release (ER) portion; and (iii) one or more pharmaceutically acceptable excipients.
16. The tablet of claim 13, wherein said immediate release (IR) portion comprises about 18 mg to about 66 mg of minocycline.
17. The tablet of claim 13, wherein said extended release (ER) portion comprises about 54 mg to about 132 mg of minocycline.
18. The tablet of claim 13, wherein said tablet comprises one or more cushioning agent(s) selected from microcrystalline cellulose, silicified microcrystalline cellulose, calcium phosphate, mannitol, sorbitol, polyethylene glycol, sodium stearyl fumarate, magnesium stearate, starch, talc and the like, or mixtures thereof.
19. The tablet of claim 18, wherein said cushioning agents are present in an amount of about 40% to about 60% by weight of the tablet.
20. The tablet of claim 13, wherein said tablet exhibits bioequivalence to a corresponding SOLODYN® tablet when administered to human subjects in fasting and fed conditions, wherein said bioequivalence is established by: (a) a 90% Confidence Interval for mean Cmax, which is between 80% and 125%, (b) a 90% Confidence Interval for mean AUC(O-t), which is between 80% and 125% and (c) a 90% Confidence Interval for mean AUC(O-oo), which is between 80% and 125%.

21. The tablet of claim 13, wherein said tablet comprises at least one score or other means of separation mark(s) for dividing the tablet into two or more equal subunits to provide a predictable and accurate fractional dose of minocycline.
22. The tablet of claim 21, wherein said tablet provides a minocycline dose of about 1 mg/kg body weight.
23. The tablet of claim 21, wherein said divided subunits have uniformity of drug content.
24. A method of orally administering once daily tablet of minocycline comprising 165mg, 135mg, 115mg, 105mg or 90mg of minocycline, wherein said tablet comprises (i) about 20 to about 40 percent of minocycline in an immediate release (IR) portion; (ii) about 80 to about 60 percent of minocycline in an extended release (ER) portion; and (iii) one or more pharmaceutically acceptable excipients, and said tablet is substantially free of lactose.
25. The method of claim 24, wherein said immediate release (IR) and extended release (ER) portions are present in a ratio of about 20:80 to about 40:60.
26. The method of claim 24, wherein said immediate release (IR) portion comprises about 18 mg to about 66 mg of minocycline and said extended release (ER) portion comprises about 54 mg to about 132 mg of minocycline.
27. The method of claim 24, wherein said tablet comprises at least one score or other means of separation mark(s) for dividing the tablet into two or more equal subunits to provide a predictable and accurate fractional dose of minocycline.
28. The method of claim 27, wherein said tablet provides a minocycline dose of about 1 mg/kg body weight.
29. The method of claim 27, wherein said tablet comprising 135mg of minocycline is (i) dispensed as intact to subjects having body weight of lll-136kg, (ii) divided into two equal subunits of 67.5mg strengths of minocycline and dispensed to subjects having body weight of 60-84kg, or (iii) divided into three equal subunits of 45mg strengths of minocycline and dispensed to subjects having body weight of 40-49kg.
30. The method of claim 27, wherein said tablet comprising 105mg of minocycline is (i) dispensed as intact to subjects having body weight of 85-110kg, (ii) divided into two equal subunits of 52.5mg strengths of minocycline and dispensed to subjects having body weight of 45-59kg, or (iii) divided into three subunits of 35mg strengths of minocycline and dispensed to subjects having body weight of 35-39kg.